Abbott Laboratories ( ABT +1.49%) more or less met analyst estimates in its first quarter, the results of which were ...
They offer investors very different value propositions.
By Siddhi Mahatole and Puyaan Singh April 16 (Reuters) - Abbott cut its annual profit forecast on Thursday due to an impact ...
Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system.
Whether Abbott Laboratories (NYSE: ABT) stock is at a good entry point depends on your investment horizon and tolerance for ...
Abbott Laboratories continues to grapple with falling sales in its nutrition segment.
Abbott (ABT) drops 4.5% after earnings and lowered 2026 EPS guidance; see top healthcare ETFs with big ABT exposure and ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected ...
Abbott beats Q1 earnings but trims guidance after $21B Exact Sciences acquisition. Medical devices grow 8.5% while nutrition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results